Alligator Bioscience AB Interim report January-March 2017

Lund, Sweden – Alligator Bioscience AB (Nasdaq Stockholm; ATORX) today announced its report for the first quarter 2017.

“In the first quarter of 2017, Alligator continued to advance our promising product portfolio, which includes five immuno-oncology drug programs with first- or best-in-class potential. In particular, we successfully completed the first Phase I study with ADC-1013, our CD40 agonistic immuno-oncology antibody, ahead of time, says Per Norlén, CEO.”

Q1 in brief

Business highlights

  • First clinical phase I study with immuno-oncology CD40 agonist antibody ADC-1013 completed in March.
  • The company has increased the number of employees with 11%, all in R & D.
  • Second production phase started for ATOR-1015.

Significant events after the reporting period

  • No significant events have occurred after the reporting period.

Financial summary

  • Net sales 2.5 (43.4) MSEK.
  • Operating result for the period -19.1 (24.1) MSEK.
  • Profit/loss for the period -19.5 (23.6) MSEK.
  • Earnings per share -0.27 (0.40) SEK.
  • Cash and cash equivalents 640 (659) MSEK.
  • 1 275 000 (0) warrants have been redeemed to an equal number of shares during the first quarter

Financial summary (Group)

2017
Jan-Mar
2016
Jan-Mar
2016
Jan-Dec
Net sales, TSEK (SEK thousand) 2 523 43 360 58 240
Profit/loss for the period, TSEK -19 502 23 599 -48 356
Cash flow for the period, TSEK -18 849 -21 303 287 135
Cash and cash equivalents, TSEK 639 739 343 718 659 136
Equity ratio, % 98% 95% 96%
R&D costs as % of operating costs excluding impairments 67,7% 55,2% 64,3%
Earnings per share before dilution, SEK -0.27 0.40 -0.80
Earnings per share after dilution, SEK -0.27 0.39 -0.80
Average number of employees 38 30 31


For further information, please contact:

Per Norlén, CEO

Telephone: + 46 46 286 42 80 (switchboard)
E-mail: per.norlen@alligatorbioscience.com

Rein Piir, VP Investor Relations at Alligator

Telephone: +46 708 537292
E-mail: rein.piir@alligatorbioscience.com

Per-Olof Schrewelius, CFO

Telephone: +46 46 286 42 85
E-mail: per-olof.schrewelius@alligatorbioscience.com

This information is such information as Alligator Bioscience AB (publ) is obligated to disclose in accordance with EU market abuse regulation. The information was submitted, through the above contact persons, for publication on 2 May 2017 at 15:30 (CET)

About Alligator

Alligator is a biotechnology company that develops innovative immune activating antibody drugs for tumor-directed immunotherapy. The Company has a pipeline of lead clinical and preclinical product candidates: ADC-1013, ATOR-1015 and ATOR-1016 as well as various research candidates. In August 2015, ADC-1013 was out-licensed to Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, for further development and commercialization. The Company’s shares are listed on Nasdaq Stockholm under the ticker “ATORX”. The Company is headquartered in Lund, Sweden, and has approximately 40 employees. For more information, please visit www.alligatorbioscience.com .


Tags:

About Us

Alligator Bioscience discovers and develops innovative antibody based immunotherapies for the treatment of cancer. Alligator Drug Discovery and Development span early research phases with lead identification up to proof of concept phase I/II clinical studies in cancer patients. In the discovery of novel antibody based drugs, Alligator uses its proprietary technology platforms FIND® and ALLIGATOR-GOLD®. FIND® (Fragment INduced Diversity) is an antibody optimization technology based on single-stranded DNA allowing generation of antibodies with significant clinical benefits. ALLIGATOR-GOLD® is a synthetic svFv library containing several billion distinct fully human antibodies. Alligator Bioscience AB was founded in 2001 and is a privately held company, located at Medicon Village in Lund, Sweden.Alligators largest shareholders are the Copenhagen-based venture fund Sunstone Capital and DUBA AB, a fully-owned subsidiary of Investor AB, as well as some private individual investors.